Blonie Dudney, MD
Retina Specialist · Florissant, MONPI 1003019019
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (53.4%), ownership interests and food and beverage — rather than concentrated in one kind of arrangement. US Retina LLC accounts for 88.4% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2022 at $7,245 and has fallen 98.6% since, to $99 in 2025.
Across 52 payments — averaging $199.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$9K
- Genentech USA, Inc.$362
- Apellis Pharmaceuticals, Inc.$179
- Alcon$158
- Regeneron Healthcare Solutions, Inc.$142
- Bausch & Lomb, A Division Of Bausch Health US, LLC$113
- plus $246 from 5 others
What the payments were for
- Food & beverage$1,20112%
- Ownership interest$3,63035%
- Other$5,54353%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 6 | $9,173 |
| Genentech USA, Inc. | 17 | $362 |
| Apellis Pharmaceuticals, Inc. | 3 | $179 |
| Alcon | 9 | $158 |
| Regeneron Healthcare Solutions, Inc. | 6 | $142 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $113 |
| Astellas Pharma US Inc | 3 | $95 |
| Alimera Sciences, Inc. | 3 | $59 |
| AbbVie(2 entities) | 2 | $50 |
| Harrow Eye, LLC | 1 | $26 |
| Eyevance Pharmaceuticals LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Syfovre$141
- enVista MX60 IOL$113
- STELLARIS$113
How this compares
$10,374 in reported general payments places this provider in the 75th percentile of 45 retina specialist providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 21 | $16,658 |
| LumiganBimatoprost | 22 | $7,529 |
| Ketorolac Tromethamine | 364 | $6,038 |
| Brimonidine Tartrate | 146 | $4,545 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 106 | $4,325 |
| Loteprednol Etabonate | 19 | $1,769 |
| Prednisolone Acetate | 46 | $1,768 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 146 | $1,743 |
| Latanoprost | 78 | $927 |
| Atropine Sulfate | 17 | $461 |
| Dorzolamide Hcl | 15 | $246 |
| Diclofenac Sodium | 11 | $178 |
| Tobramycin | 33 | $140 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $50 | $24,18743 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $113 | $1,76919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 45 retina specialist providers in Missouri.
Other retina specialist in Florissant
- Carla TerritoFlorissant$21K
- David GlaserFlorissant$20K
- Clayton ScanlonFlorissant$3K
- Kevin BlinderBrentwood$333K
- Aaron LeeSaint Louis$214K
- Sabin DangBrentwood$174K
- Athanasios PapakostasBrentwood$85K
- Alia DurraniBrentwood$53K
- Barton BlackorbyBrentwood$31K
- Ollya FromalBrentwood$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.